# Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.

> **NCT07266480** · PHASE2 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 142 (estimated)

## Conditions studied

- Squamous Oesophageal Cancer

## Interventions

- **DRUG:** Adebrelizumab

## Key facts

- **NCT ID:** NCT07266480
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07266480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07266480, "Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07266480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*